Western Australia Branch

Branch Councillor

Name: Connie Jacakman
Position: Early Career Fevelopment Fellow
Address/affiliation: CHIRI BioScience, Curtin University
Email address: connie.jackaman@curtin.edu.au

Branch Information

The WA branch aims to provide opportunities for Perth immunologists and students to stay up to date with the latest immunology research in our state, as well as from across the country and overseas. We arrange regular catered seminars at different sites across WA, where you can hear interesting speakers and meet your colleagues in a relaxed environment. We also host a bi-annual, Perth Immunology Group meeting, student events and activities to promote immunology in the community.

We are always open to comments, suggestions and feedback so please free to contact Connie or one of our committee members.

WA organising committee: Connie Jackaman, Demelza Ireland (treasurer), Scott Fisher (secretary), Andrew Currie, Senta Walton, Dino Tan, Alistair Cook, Mark Agostino, Federica Tomay and Melanie McCoy. Student  sub-committee: Wayne Aston and Amy Prosser.

Jobs in Western Australia

Please see the Positions Vacant for the latest positions available in Western Australia.

Upcoming Events

In the News:

DREAM TRIAL A NEW HOPE IN MESOTHELIOMA TREATMENT

DREAM trial press releaseDREAM TRIAL A NEW HOPE IN MESOTHELIOMA TREATMENT

A new clinical trial combining immunotherapy with chemotherapy for the first time in treating the asbestos cancer mesothelioma has just opened at Sir Charles Gairdner Hospital in Perth. The DREAM study is a phase 2 trial of the anti-programmed cell death ligand-1 (PD-L1) checkpoint inhibitor, durvalumab, combined with first line chemotherapy currently used in mesothelioma.  The study was initiated by Professor Anna Nowak and Dr Joost Lesterhuis, both senior researchers at UWA’s National Centre for Asbestos Related Diseases in Perth.  Through the Australasian Lung Cancer Trials Group (ALTG) the study will be run at 12 centres across Australia and the collection of samples and coordination of the trial will be handled by the NHMRC Clinical Trials Centre at the University of Sydney. The pharmaceutical company AstraZeneca has provided $1.5 million to fund the study. An important aspect of this trial for both NCARD and Sir Charles Gairdner Hospital is that Dr Lesterhuis will run the correlative study on blood and tumour tissue taken from patients who have agreed to participate, and these samples will be examined for predictors of who is benefitting most.